BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Europabio - ECPv6.15.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Europabio
X-ORIGINAL-URL:https://www.europabio.org
X-WR-CALDESC:Events for Europabio
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/Brussels
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20220327T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20221030T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20230326T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20231029T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20240331T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20241027T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20250330T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20251026T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20240214T080000
DTEND;TZID=Europe/Brussels:20240214T170000
DTSTAMP:20260526T205725
CREATED:20240130T125205Z
LAST-MODIFIED:20240130T125207Z
UID:7333-1707897600-1707930000@www.europabio.org
SUMMARY:Europe Rare Disease Summit 2024
DESCRIPTION:How to improve and learn about Government Plans\, Access & Financing\, Clinical Research and Innovation\, Artificial Intelligence and Data\, and Social & Patient. \n\n\n\nJoin our very own Healthcare Policy Senior Manager\, Adrien Samson in Madrid where he will be speaking in the panel “Innovation\, Funding and Access to Orphan Drugs: Challenges and Opportunities” between 12:15 and 13:00. \n\n\n\n \n\n\n\nWe are thrilled to announce the eagerly awaited second edition of the Europe Rare Disease Summit\, set to take place in February. Joining forces from all corners of Europe\, this prestigious event brings together leading researchers\, healthcare professionals\, patient advocates\, policymakers\, industry experts\, and rare disease patients and families. \n\n\n\nThe summit emphasizes the power of collaboration and solidarity in facing rare diseases. Together\, we can accelerate research\, enhance patient care\, and improve outcomes\, offering a brighter future for those affected by rare diseases. \n\n\n\nKey Objectives: \n\n\n\nEmpowering Patients: Putting patients at the heart of our efforts\, we strive to enhance their access to quality care and support\, while advocating for their rights and unique challenges. \n\n\n\nAdvancing Research: Renowned scientists will present groundbreaking discoveries\, fostering cross-disciplinary collaboration to propel rare disease research forward. \n\n\n\nBuilding Collaborative Networks: A platform for stakeholders to connect\, exchange ideas\, and form strategic partnerships\, bridging gaps in research\, treatment\, and support. \n\n\n\nInfluencing Policy: By engaging policymakers\, we seek to drive positive changes and better support the rare disease community. \n\n\n\nEngaging Program Highlights: Expect a dynamic lineup of keynote speeches\, interactive workshops\, panel discussions and networking opportunities. Share experiences\, learn from experts\, and inspire change. \n\n\n\nLocation and Dates: Prepare to be inspired in the vibrant setting of Madrid on February 14th. \n\n\n\nWho will Attend: \n\n\n\nRare Disease AdvocatesResearchers and ScientistsHealthcare ProfessionalsIndustry LeadersPolicymakers and Government RepresentativesPharmaceutical and Biotech CompaniesInvestors and Venture CapitalistsAcademics and Students
URL:https://www.europabio.org/event/europe-rare-disease-summit-2024/
CATEGORIES:External,Healthcare Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2024/01/Event-Banner-ERDS-2024.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20240124T120000
DTEND;TZID=Europe/Brussels:20240124T150000
DTSTAMP:20260526T205725
CREATED:20240109T104014Z
LAST-MODIFIED:20240116T095205Z
UID:7234-1706097600-1706108400@www.europabio.org
SUMMARY:EU pharmaceutical legislation - Europe’s biotech innovation in the balance?
DESCRIPTION:Event agenda \n\n\n\n12:00: Registration opens \n\n\n\n12:30: Panel starts \n\n\n\n13:45: Panel close and networking lunch \n\n\n\n15:00: Close \n\n\n\nConfirmed Speakers \n\n\n\nTomislav Sokol MEPMember SANT Committee\, European Parliament \n\n\n\nHilde StevensCo-director\, Institute for Interdisciplinary Innovation in Healthcare (I3H)\, ULB \n\n\n\nKristin ThompsonChief Operating Officer\, eureKARE \n\n\n\nVivian TsevelekiChief Operating Officer\, theraCell \n\n\n\nMore to be announced soon \n\n\n\nIntroduction \n\n\n\nIn April 2023\, the European Commission adopted a proposal for a new Directive and a new Regulation\, aimed at revising and replacing the existing General Pharmaceutical Legislation (GPL). The proposal focuses on modernising the pharmaceutical sector with a patient-centred approach\, while also fully supporting an innovative and competitive industry. \n\n\n\nThrough the proposal\, the EU aims to offer an attractive and innovation-friendly environment for research\, development\, and production of medicines in Europe. The EU plans to create this environment by promoting world-class innovation\, governed by stable and consistent rules that keep pace with innovation and which increase competitiveness while reducing red tape and costs. \n\n\n\nOne of the sectors impacted by the proposal is that of biotechnology\, which has been instrumental in the discovery and development of therapies\, diagnostics\, vaccines and\, most importantly\, advanced medicines. These ‘next generation medicines’ are delivered through a complex and interdependent biotechnology ecosystem\, where companies of all sizes contribute to establishing a pathway to patients. \n\n\n\nJoin this Euractiv Hybrid Conference to discuss Europe’s biotech innovation in light of the EU’s reform of the General Pharmaceutical Legislation.  \n\n\n\nQuestions to be discussed include: \n\n\n\n\nHow can Europe’s biotechnology industry maintain its competitiveness in the global medical market?\n\n\n\nHow can we establish a framework that fosters the growth of small biotech innovators?\n\n\n\nWhat are the reactions of investors to the challenges faced by small biotech companies\, and how do these reactions influence the trajectory of innovation in the biotech industry?\n\n\n\nWhat strategies can be employed to establish a successful innovation pathway for biotech companies\, while considering and aligning with the objectives of the reformed GPL?
URL:https://www.europabio.org/event/eu-pharmaceutical-legislation-europes-biotech-innovation-in-the-balance/
CATEGORIES:All,EuropaBio,External,Healthcare Biotech,SME Platform
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2024/01/EuropaBio.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20240110T080000
DTEND;TZID=Europe/Brussels:20240125T170000
DTSTAMP:20260526T205725
CREATED:20231213T130812Z
LAST-MODIFIED:20231213T131255Z
UID:7175-1704873600-1706202000@www.europabio.org
SUMMARY:IHI Call Days - Calls 6 & 7
DESCRIPTION:The IHI Call Days are your one-stop-shop to get detailed information on our calls for proposals and network with potential partners for your consortium. \n\n\n\nIHI call 7 (single-stage) – info sessions\n\n\n\n10-12 January 2024 \n\n\n\nCall 7\, topic 1: Improving clinical management of heart disease from early detection to treatmentWednesday 10 January | 10:30-11:30 \n\n\n\nCall 7\, topic 2: User-centric technologies and optimised hospital workflows for a sustainable healthcare workforceWednesday 10 January | 14:30-15:30 \n\n\n\nIHI rules and procedures for single-stage callsThursday 11 January | 10:30-11:30 \n\n\n\nCall 7\, topic 3: Clinical validation of biomarkers for diagnosis\, monitoring disease progression and treatment responseThursday 11 January | 14:30-15:30 \n\n\n\nManaging the financial aspects of proposals for single-stage callsFriday 12 January | 10:30-11:30 \n\n\n\nIHI call 6 (two-stage) – info sessions\n\n\n\n15-16 January 2024 \n\n\n\nIHI rules and procedures for two-stage callsMonday 15 January | 14:30-15:30 \n\n\n\nCall 6\, topic 2: Development of practical guidance and recommendations for using real world data/real world evidence in healthcare decision-makingTuesday 16 January | 10:30-11:30 \n\n\n\nCall 6\, topic 1: Support healthcare system resilience through a focus on persistency in the treatment of chronic diseasesTuesday 16 January | 14:30-15:30 \n\n\n\nIHI call 7 (single-stage) – pitching sessions\n\n\n\n23-25 January 2024 \n\n\n\nCall 7\, topic 1: Improving clinical management of heart disease from early detection to treatmentTuesday 23 January | 14:30-16:00 \n\n\n\nCall 7\, topic 2: User-centric technologies and optimised hospital workflows for a sustainable healthcare workforceWednesday 24 January | 14:30-16:00 \n\n\n\nCall 7\, topic 3: Clinical validation of biomarkers for diagnosis\, monitoring disease progression and treatment responseThursday 25 January | 14:30-16:00
URL:https://www.europabio.org/event/ihi-call-days-calls-6-7/
CATEGORIES:Healthcare Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2023/12/news-cover.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20231201T083000
DTEND;TZID=Europe/Brussels:20231201T094500
DTSTAMP:20260526T205725
CREATED:20231031T084455Z
LAST-MODIFIED:20231031T084520Z
UID:7041-1701419400-1701423900@www.europabio.org
SUMMARY:EFIB 2023 Rotterdam Statement wider launch
DESCRIPTION:Industrial biotechnology for a sustainable and resilient global Europe  \n\n\n\nAs the EU looks ahead to the European elections in 2024\, with a new EU Commission mandate and Work Programme\, EuropaBio reviews European strategies and ambitions where biotechnology plays a key role. Ursula von der Leyen’s State of the European Union address of 13 September announced an ‘EU Biotech and Biomanufacturing Initiative’. The announced EU initiative is the latest indication of a greater point of recognition and acceleration for biotechnology. \n\n\n\nBuilding on this momentum\, the EFIB Rotterdam Statement of 2023 provides a priority pathway for biotechnology to support Europe’s global leadership\, resilience and competitiveness. \n\n\n\nWe invite you to join us for a discussion on the role and potential of biotechnology and Europe’s global position in the context of the 2024 EU election. \n\n\n\n\nInvitation Only Event
URL:https://www.europabio.org/event/efib-2023-rotterdam-statement-wider-launch/
CATEGORIES:EFIB,EuropaBio,Industrial Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2023/10/Vilnius-Statement-Event-600-×-260px.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20231130T143000
DTEND;TZID=Europe/Brussels:20231130T160000
DTSTAMP:20260526T205725
CREATED:20231018T092656Z
LAST-MODIFIED:20231018T113625Z
UID:7003-1701354600-1701360000@www.europabio.org
SUMMARY:EuropaBio Patient BioForum 2023 Roundtable on Advancing Solutions for Unmet Medical Needs
DESCRIPTION:Hybrid Event | Invitation Only \n\n\n\n\n\nEuropaBio’s Patient BioForum meets annually to facilitate the exchange of views and expertise on scientific\, regulatory\, and policy issues between patient organisations and the biopharmaceutical industry. \n\n\n\nIn recent years\, unmet medical needs have been at the core of Europe’s pharmaceutical and public health policies. To address unmet medical needs (UMN)\, the Commission proposed as part of the revision of the EU General Pharmaceutical Legislation (GPL) to introduce a definition of UMN and a definition of high UMN. Under the Commission’s proposals\, all orphan products would qualify as addressing UMN but only a subset of products would meet the HUMN criteria. The Commission’s proposals on UMN and especially HUMN received mixed reactions from patient organisations and negative reactions from the industry. \n\n\n\nOn 1 December 2022\, EuropaBio organised a Patient BioForum which brought together industry and patient organisations to discuss the topic of UMN in view of reaching a common understanding on UMN. Those discussions revealed shared interests and concerns with the possible approach to UMN in the EU Pharmaceutical Legislation. The discussions were followed by a report which outlined recommendations to policymakers to enable Europe to address the challenge of UMN. \n\n\n\nWith the proposals now presented and being negotiated by the European Parliament and the Council\, the 2023 Patient BioForum is an opportunity to build on the 2022 Patient BioForum to foster exchanges between patient groups and industry on UMNs\, including expectations from the legislation and beyond. The 2023 Patient BioForum will also be an opportunity to issue multi-stakeholder recommendations to policymakers to ensure the GPL is fit for purpose to address patients need and support innovation.   \n\n\n\n \n\n\n\nProgramme \n\n\n\nThe 2023 Patient BioForum will be held in a roundtable format under Chatham House Rule. A wide range of stakeholders representing patients\, regulators\, policy-makers\, and industry will be invited to take part in the roundtable. All participants will be invited to take an active part in the discussion to bring their unique perspective. The roundtable will be followed by a report to summarise the discussions. \n\n\n\n1. Introductions \n\n\n\n2. Legislating Unmet Medical Needs: Perspectives from the European Commission and the European Parliament \n\n\n\n3. Roundtable topic 1:  How Can the EU Pharmaceutical Legislation Help Stimulate Patient-Centric Innovation? \n\n\n\n4. Roundtable topic 2: How can Europe Incentivise R&D for UMN and Underserved Areas? \n\n\n\n5. Conclusions \n\n\n\nIf you would like to attend\, please contact Adrian Lincoln\, a.lincoln@europabio.org
URL:https://www.europabio.org/event/europabio-patient-bioforum-2023-roundtable-on-advancing-solutions-for-unmet-medical-needs/
CATEGORIES:EuropaBio,Healthcare Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2023/10/Event-Banners-Website-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20231106T153000
DTEND;TZID=Europe/Brussels:20231106T163000
DTSTAMP:20260526T205725
CREATED:20231013T105949Z
LAST-MODIFIED:20231013T105951Z
UID:6985-1699284600-1699288200@www.europabio.org
SUMMARY:BIO Europe 2023
DESCRIPTION:The European Pharmaceutical Legislation – Will it keep the light on for biotech in Europe? \n\n\n\nJoin our Director General\, Dr. Claire Skentelbery on the 6th of November in Munich for her panel discussing what the legislation brings\, its potential impact on businesses and what needs to be done to change the legislation in its journey to a final version\, that it works for both\, the biotech ecosystem\, maintaining innovation pipelines\, and patients.
URL:https://www.europabio.org/event/bio-europe-2023/
CATEGORIES:External,Healthcare Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2023/10/Screenshot-2023-10-13-113155.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20231101T080000
DTEND;TZID=Europe/Brussels:20231102T170000
DTSTAMP:20260526T205725
CREATED:20231013T082312Z
LAST-MODIFIED:20231013T082314Z
UID:6977-1698825600-1698944400@www.europabio.org
SUMMARY:World Orphan Drug Congress
DESCRIPTION:The World Orphan Drug Congress is the largest and most established orphan drugs & rare diseases meeting of its kind across the globe. \n\n\n\nJoin our Director General\, Dr. Claire Skentelbery on the 1st of November for her Keynote Panel: How to navigate the new legislation to enable orphan drug developers to stay innovative and profitable in Europe. \n\n\n\nAs well as on the 2nd on November for her Panel: How to enable SME’s to obtain greater market access.
URL:https://www.europabio.org/event/world-orphan-drug-congress/
CATEGORIES:External,Healthcare Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2023/10/Screenshot-2023-10-13-101414.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20231024T080000
DTEND;TZID=Europe/Brussels:20231025T170000
DTSTAMP:20260526T205725
CREATED:20230413T124141Z
LAST-MODIFIED:20230525T155522Z
UID:6110-1698134400-1698253200@www.europabio.org
SUMMARY:EFIB 2023 - Industrial biotechnology for a sustainable and resilient global Europe
DESCRIPTION:EuropaBio is pleased to announce that this year’s edition of EFIB\, Europe’s Leading Event on Industrial Biotechnology and the Bioeconomy under the title ‘Industrial biotechnology for a sustainable and resilient global Europe’\, will take place 24-25 October 2023 in Rotterdam\, The Netherlands. EuropaBio is partnering with local hosts HollandBio and ChemistryNL to bring EFIB 2023 to Rotterdam. \n\n\n\nNow in its 16th year\, EFIB will be dedicated to exploring how industrial biotechnology and the bioeconomy supports European competitiveness. EFIB brings together professionals from across the value chain to discuss advancements from industrial biotechnology and its contribution towards positioning Europe as a global leader in addressing societal and sustainability challenges. Participants include industry of all sizes\, as well as the community that enables industry to deliver\, including researchers\, policy makers\, regulators\, and global organisations. \n\n\n\nOur two-day programme includes inspiring plenaries\, a start-up pitching hour and will explore our four thematic areas – Food\, Feed & Nutrition; Sustainable Biomaterials; Bioprocesses & Technologies; and Sustainable Finance – as well as new frontiers like biomanufacturing. The programme is complemented by the exhibition: including start-ups and SMEs in our SME Village\, the academic poster presentation in our Innovation Campus\, and exhibitors from industry and national associations. Interested in exhibiting? Check out our sponsorship page.   \n\n\n\nAttending EFIB 2023 will allow you to learn about the latest market trends and research findings in industrial biotechnology and network with key stakeholders.  \n\n\n\n\nRegister Here\n\n\n\n\nFor more information visit our website and subscribe to our newsletter.
URL:https://www.europabio.org/event/efib-2023-industrial-biotechnology-for-a-sustainable-and-resilient-global-europe/
CATEGORIES:EFIB
ATTACH;FMTTYPE=image/jpeg:https://www.europabio.org/wp-content/uploads/2023/04/Copy-of-General-template-1.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20231023T124000
DTEND;TZID=Europe/Brussels:20231023T141000
DTSTAMP:20260526T205725
CREATED:20231012T114428Z
LAST-MODIFIED:20231012T115640Z
UID:6973-1698064800-1698070200@www.europabio.org
SUMMARY:TOPRA Symposium 2023: advancing global healthcare together
DESCRIPTION:Session: Update on EU new regulatory legislation and a view from different angles \n\n\n\nJoin our very own Valentin Plouchard who will be speaking at the TOPRA Annual Symposium in Lisbon on the 23rd of October.
URL:https://www.europabio.org/event/topra-symposium-2023-advancing-global-healthcare-together/
CATEGORIES:External,Healthcare Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2023/10/Screenshot-2023-10-12-133359.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20231011T133000
DTEND;TZID=Europe/Brussels:20231011T150000
DTSTAMP:20260526T205725
CREATED:20230920T110911Z
LAST-MODIFIED:20230920T110912Z
UID:6861-1697031000-1697036400@www.europabio.org
SUMMARY:SMEs in a Changing World: The Impact of the Revision of the Pharmaceutical Legislation on Europe’s innovative SMEs
DESCRIPTION:In April 2023\, the European Commission published new legislative proposals to revise the EU’s long-standing pharmaceutical legislation and ensure it can meet the challenges of the 21st century. The revision will redefine the regulatory framework for medicines and have a significant impact on the global innovation ecosystem. \n\n\n\nAs emerging and small companies have become innovation drivers\, responsible for over two-thirds of the R&D pipeline that will become the medicines of tomorrow\, changing the rule book that has helped build Europe’s small company ecosystem over the last 20 years is going to have consequences for start-ups\, emerging and small companies looking to first enter the market but also on mid-size companies looking for growth opportunities in Europe. \n\n\n\nThis event will be an opportunity to highlight the role of small and mid-size companies in developing medicines for patients\, assess the foreseeable impacts of the revision on those companies\, and hear directly from them what they need from the revision to continue their journey in Europe.
URL:https://www.europabio.org/event/smes-in-a-changing-world-the-impact-of-the-revision-of-the-pharmaceutical-legislation-on-europes-innovative-smes/
CATEGORIES:EuropaBio,External,Healthcare Biotech,SME Platform
ATTACH;FMTTYPE=image/jpeg:https://www.europabio.org/wp-content/uploads/2023/09/Event-Banners-Website.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20230929T100000
DTEND;TZID=Europe/Brussels:20230930T190000
DTSTAMP:20260526T205725
CREATED:20230320T153927Z
LAST-MODIFIED:20230320T160626Z
UID:6049-1695981600-1696100400@www.europabio.org
SUMMARY:International Forum on Industrial Biotechnology and Bioeconomy (IFIB)
DESCRIPTION:NETWORKING AND PARTNERSHIPS IN BIOECONOMY AREA \n\n\n\nIFIB – International Forum on Industrial Biotechnology and Bioeconomy aims at strengthening the bioeconomy network in the Euro-Mediterranean area and to promote partnerships. The focus of the Forum is biotechnology\, as provider of new resources for industries. \n\n\n\nIt is organized into round-tables and sessions devoted to specific sub-sectors of industrial biotechnology: bio-based industries\, agro-food\, energy\, environment policies on industrial biotech and bioeconomy\, involving international speakers coming from key sector’s players. \n\n\n\nEdition 2023 > 29/30 September Bari \n\n\n\n\nMore information
URL:https://www.europabio.org/event/international-forum-on-industrial-biotechnology-and-bioeconomy-ifib/
CATEGORIES:External,Industrial Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2023/03/Event-Page-3.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20230926T100000
DTEND;TZID=Europe/Brussels:20230928T190000
DTSTAMP:20260526T205725
CREATED:20230320T145053Z
LAST-MODIFIED:20230320T145327Z
UID:6038-1695722400-1695927600@www.europabio.org
SUMMARY:BIOSPAIN 2023
DESCRIPTION:BIOSPAIN is the largest biotech event organized by a national bioindustry association in Europe and one of the largest in the world by the number of one-to-one meetings and companies participating. 34% of our delegates came from outside of Spain. \n\n\n\nThis year\, BIOSPAIN goes back to Barcelona\, the main biotech cluster in Spain and one of the most dynamic cities in the world. \n\n\n\nThe event will take place in Pavilion 1 – Fira de Barcelona – Montjuïc. It stands in a superb location in the city center\, easily accessible from the airport and well-connected to the public transport network. It is located in Montjuïc Park\, an area of cultural and historical interest thanks to its museums and theatres and it also features some of the main tourist attractions in Barcelona. \n\n\n\n\nMore information
URL:https://www.europabio.org/event/biospain-2023/
CATEGORIES:External,Industrial Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2023/03/Event-Page-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20230925T120000
DTEND;TZID=Europe/Brussels:20230925T131500
DTSTAMP:20260526T205725
CREATED:20230710T072650Z
LAST-MODIFIED:20230925T072852Z
UID:6450-1695643200-1695647700@www.europabio.org
SUMMARY:The economic power of biotechnology for Europe
DESCRIPTION:The world is at a key point of industrial and societal transition\, driven by advancing technology and the need for competitive\, resilient and sustainable economies. \n\n\n\nBiotechnology is at the heart of this transition across all sectors and it is playing a significant role in shaping Europe’s future. \n\n\n\nEuropean Biotech Week kick starts with a look at how biotechnology performs in the European Union’s economy. \n\n\n\nProfessor Dennis Ostwald\, founder and CEO of the WifOR Institute presents the 2023 edition of EuropaBio’s ‘Measuring the economic footprint of the biotechnology industry in Europe’. Professor Ostwald showcases how biotechnology contributes across healthcare and industrial sectors in the light of Europe’s response to Covid\, global supply chains stressed further by the Russian invasion of Ukraine\, and at a time when Europe also has ambitious climate change goals. \n\n\n\nSpeakers: \n\n\n\nProfessor Dr. Dennis A. Ostwald. Through his studies\, Prof. Ostwald aims to make the importance of health innovations visible and enable evidence-based decision making for a healthy society. He conducts research on topics such as health economics\, the value of impacts\, and international social policy. Prof. Ostwald studied Industrial Engineering and Management at the Technical University of Darmstadt\, Germany and received his PhD from the Chair of Finance and Economic Policy\, Prof. Dr. Dr. h.c. Bert Rürup\, on the topic “Growth and employment effects of the healthcare industry”. As Professor of Economic Research and International Management at the Steinbeis School of International Business and Entrepreneurship (SIBE)\, he wants to develop young talents into responsible managers who understand the interplay between social\, environmental and economic sustainability.  \n\n\n\n \n\n\n\nJoin EuropaBio to understand how biotechnology is increasing its role with Europe’s economy and discuss with Members what this means for sectors\, countries and citizens. \n\n\n\n\nRegister here
URL:https://www.europabio.org/event/the-economic-power-of-biotechnology-for-europe/
CATEGORIES:Biotech Week
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2023/07/GENERAL-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20230920T080000
DTEND;TZID=Europe/Brussels:20230921T170000
DTSTAMP:20260526T205725
CREATED:20230615T070358Z
LAST-MODIFIED:20230615T070523Z
UID:6387-1695196800-1695315600@www.europabio.org
SUMMARY:Life Sciences Baltics as a contributor to Lithuania’s innovation ecosystem
DESCRIPTION:Life sciences in Lithuania have been a priority for the government for over a decade. Accelerating faster than almost anywhere else in Europe\, the sector aims to contribute 5% to Lithuania’s GDP by 2030. The close cooperation between actors of the ecosystem is one of the reason for success.   \n\n\n\nCreative collaboration takes place in Lithuania’s innovation ecosystem in a variety of ways\, including events\, cross-promotion\, and sharing of resources. The leading life sciences Baltics event in the region – Life Sciences Baltics – is one of the best examples of these collaborations. \n\n\n\nSince its initiation in 2012\, the forum has aimed to create as many opportunities as it is possible for deeper cooperation between the growing life sciences ecosystems in the Baltics and international partners. \n\n\n\nHeld every two years\, the forum has grown from a 300-person assembly to a community of up to 800 key participants from around 40 countries: corporate CEOs\, startup founders\, tech scouts\, investors\, researchers. It is the largest life sciences event in the Eastern and Central Europe. \n\n\n\nThe event will take place in the Lithuania’s capital city of Vilnius on September 20-21. The pre-registration is already open for participants and exhibitors. \n\n\n\nWhether there is a need to kick off the project\, generate leads\, or engage in valuable partnerships\, Life Sciences Baltics offers a diverse range of interactions for its participants: international conference\, exhibition\, networking spaces\, pitch challenge for startups. \n\n\n\nIt also hosts business delegations and offers an opportunity for side visits to Lithuania’s organizations and institutions. \n\n\n\nThe program of the international conference is divided into sessions with the most trending topics worldwide that are also breakthrough areas in the Baltic countries: gene editing\, CRISPR diagnostics\, AI and digital health innovations\, nanomedicine\, microbiome\, reinvention of clinical trials\, digital biomarkers and many more. \n\n\n\nMany big names have attended Life Sciences Baltics\, among them Thermo Fisher Baltics\, Johnson&Johnson\, Clarivate\, Novartis\, Abbvie\, AstraZeneca\, and others. Nobel prize winners Richard Henderson\, Brian Kobilka\, Dan Shechtman\, CRISPR pioneer Prof. Dr Virginijus Šikšnys were among top conference speakers. \n\n\n\nThe event will keep tabs on the fastest growing startups in the region\, but only 10 hand-picked startups will have an opportunity to showcase who they are in front of a panel of investors. \n\n\n\nThe event is organized by Innovation Agency Lithuania\, an official public agency responsible for the Lithuanian innovation ecosystem and is supported by Lithuania’s local ecosystem actors – Lithuanian biotechnology association\, universities\, hospitals\, business angels and Lithuania’s life sciences enthusiasts.  \n\n\n\nThe Baltics\, and Lithuania in particular\, – the next big thing in life sciences  \n\n\n\nLife Sciences Baltics make it possible to assess the attractiveness of the Baltic countries in close-up – Estonia\, Latvia and Lithuania show their distinct\, but strong potential in the sector. \n\n\n\nThree Baltic countries are particularly seeing a growth in life sciences startups. While average funding per startup is decreasing globally\, it’s increasing in the region.  Lithuania attracts growing VC interest into global solutions produced by local entrepreneurs and scientists. \n\n\n\nFocused on nurturing the next generation of talents\, the local life sciences enterprises in the Baltics excel at creativity and entrepreneurship. In 2021 alone\, Lithuania’s life sciences sector grew by almost 87% and generated revenues of 2 billion euros. \n\n\n\n90% of the output of Lithuania’s life sciences are exported to more than 100 countries worldwide. Lithuanian-made medical and pharmaceutical equipment and other products are trusted by customers in the USA\, Germany\, France\, and elsewhere. \n\n\n\nOne of the most prominent players in Lithuania is Thermo Fisher Scientific Baltics\, which has stimulated the development of Lithuania’s industry during the last decade. This company\, along with other international players in the market\, work with local actors for various R&D projects and supply chain. \n\n\n\n\nFor more details
URL:https://www.europabio.org/event/life-sciences-baltics-as-a-contributor-to-lithuanias-innovation-ecosystem/
CATEGORIES:External
ATTACH;FMTTYPE=image/jpeg:https://www.europabio.org/wp-content/uploads/2023/06/Event-Banners-Website-1.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20230704T100000
DTEND;TZID=Europe/Brussels:20230704T170000
DTSTAMP:20260526T205725
CREATED:20230614T151559Z
LAST-MODIFIED:20230614T151749Z
UID:6377-1688464800-1688490000@www.europabio.org
SUMMARY:Industrial Biotechnologies Day
DESCRIPTION:CEFIC Specialty Chemicals sector groups EFCG\, Biochem Europe and EFG\, together with SICOS\, the French industry association for Fine Chemicals and Biotech\, will jointly hold their first in-person Industrial Biotechnologies Day on July 4th\, 2023 in Brussels. \n\n\n\nSpecialists from the industry\, EU policy makers\, and civil society will come together across four panels to dive into topics such as: \n\n\n\n\nEuropean policies shaping the biotech landscape – what is needed to unleash its full potential?\n\n\n\nEuropean regulatory frameworks – an obstacle to innovation?\n\n\n\nFeedstocks and industrial capacities – what is the role of energy costs?\n\n\n\nNew technologies and future breakthroughs – what to expect and what’s at stake?\n\n\n\n\nConfirmed Speakers: \n\n\n\n\nHans Ingels\, European Commission – Directorate-General for Internal Market\, Industry\, Entrepreneurship and SMEs\n\n\n\nLudo Diels\, Flemish Institute for Technological Research (VITO)\n\n\n\nVincent Touraille\, Sicos\n\n\n\nKarel De Winter\, Bio Base Europe Pilot Plant\n\n\n\nMarcello Buson\, Olon SpA\n\n\n\nFrédéric Van Gansberghe\, Futerro\n\n\n\nClaire Skentelberry\, Europabio\n\n\n\nChristian Le Roux\, Group M21\n\n\n\nHarald Ruissenaars\, Corbion\n\n\n\nEric Bierny\, Galactic\n\n\n\nNicolas Martin\, Metex\n\n\n\nThomas Canova\, Solvay\n\n\n\nJulien Honoré\, Roquette\n\n\n\nJuliette Martin\, Seqens\n\n\n\nGwenaël Servant\, Abolis\n\n\n\n\n\nMore details
URL:https://www.europabio.org/event/industrial-biotechnologies-day/
CATEGORIES:External
ATTACH;FMTTYPE=image/jpeg:https://www.europabio.org/wp-content/uploads/2023/06/Event-Banners-Website.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20230630T124500
DTEND;TZID=Europe/Brussels:20230630T124500
DTSTAMP:20260526T205725
CREATED:20230321T210403Z
LAST-MODIFIED:20230321T210405Z
UID:6074-1688129100-1688129100@www.europabio.org
SUMMARY:DUTCH BIOTECH EVENT 2023
DESCRIPTION:Join us to celebrate the power of biotech at the Dutch Biotech Event 2023! \n\n\n\nAbout HollandBIO’s Dutch Biotech Event \n\n\n\nThe program features inspiring talks by keynote speakers on biotech and entrepreneurship\, followed by workshops and break-out sessions that contribute to your personal development and that of your company. In addition\, there will be plenty of opportunities for networking during the break\, drinks and vegetarian BBQ. \n\n\n\nWho can join Dutch Biotech Event? \n\n\n\nThe Dutch Biotech Event welcomes HollandBIO members (registration free of charge) and employees of other biotech R&D companies (registration fee €295\,- p.p.)\, with a maximum of 2 delegates per organization. \n\n\n\nWe invite non-member startups to consider a HollandBIO membership (€562\,-/year)\, which besides access to the network & events\, offers many more advantages. \n\n\n\n\nMore information
URL:https://www.europabio.org/event/dutch-biotech-event-2023/
LOCATION:Inn Style\, Herenweg 55\, Maarssen\, 3602 AN\, Netherlands
CATEGORIES:External,Industrial Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2023/03/Event-Page-2.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20230627T180000
DTEND;TZID=Europe/Brussels:20230627T200000
DTSTAMP:20260526T205725
CREATED:20230524T142640Z
LAST-MODIFIED:20230616T172415Z
UID:6330-1687888800-1687896000@www.europabio.org
SUMMARY:NAC Spanish Presidency Summer Reception
DESCRIPTION:EuropaBio\, and AseBio\, the Spanish Association of Biotechnology Companies\, with the support of Merck\, will host a summer reception to mark the beginning of the Spanish Council Presidency of the European Union and present the outcomes of their National Association Council Presidency Summit.  \n\n\n\nThe event will take place on June 27th in Brussels at Comet Meetings – Louise\, from 18-20h. If you wish for more details\, please get in touch with José Peres at j.peres@europabio.org 
URL:https://www.europabio.org/event/nac-spanish-presidency-summer-reception/
CATEGORIES:EuropaBio
ATTACH;FMTTYPE=image/jpeg:https://www.europabio.org/wp-content/uploads/2023/05/NAC-Summer-Reception-1.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20230627T140000
DTEND;TZID=Europe/Brussels:20230627T160000
DTSTAMP:20260526T205725
CREATED:20230516T093527Z
LAST-MODIFIED:20230517T184028Z
UID:6244-1687874400-1687881600@www.europabio.org
SUMMARY:Reflection seminar and closing party around the EU presidency
DESCRIPTION:On June 27\, a Life Science conference is arranged for EU parliamentarians during Sweden’s EU presidency. \n\n\n\nDirectly after the official conference\, The Royal Academy of Engineering Sciences (IVA) and SwedenBIO invites the public to a seminar with the spotlight on how the suggested EU legislations may affect the life science industry. With examples from the Swedish life science arena\, we show the importance of intellectual property and data protection in the journey from academic research to products and therapies for patients. \n\n\n\nAfterward\, a networking reception is organized by the united life science industry organisations. With drinks\, snacks\, and key speakers\, we ensure that the end of the presidency marks the start of an even stronger united life science industry in Sweden and beyond. \n\n\n\n\nMore details
URL:https://www.europabio.org/event/reflection-seminar-and-closing-party-around-the-eu-presidency/
LOCATION:IVA Conference Center\, Grev Turegatan 15\, Stockholm\, Sweden
CATEGORIES:External
ATTACH;FMTTYPE=image/jpeg:https://www.europabio.org/wp-content/uploads/2023/05/External-Events-Banners.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20230622T140000
DTEND;TZID=Europe/Brussels:20230622T160000
DTSTAMP:20260526T205725
CREATED:20230414T130232Z
LAST-MODIFIED:20230621T083523Z
UID:6128-1687442400-1687449600@www.europabio.org
SUMMARY:EuropaBio National Associations Council Summit 2023 (Spanish Presidency): A global Europe - the role of transformative legislation
DESCRIPTION:Spain will hold the Presidency of the Council of the European Union for the fifth time in the second half of 2023\, between July 1 and December 31. In a pivotal time for the Biotechnology industry\, Spain will lead the dialogue on the European Commission’s proposal on new genomic techniques (NGT) and the revision of the Pharmaceutical Strategy for Europe – critical policies for European patients\, Europe’s food security and the green transition. \n\n\n\nEuropaBio – the European Association for Bioindustries and AseBio\, the Spanish Association of Biotechnology Companies\, are proud hosts of EuropaBio’s National Associations Council (NAC) annual Presidency Summit. Invited speakers from industry\, policymakers\, and national biotechnology associations will explore the latest policy developments and offer their insights into the upcoming work and ambitions of the Spanish Council Presidency. \n\n\n\nThe Summit will be public and held online on June 22. The event will be followed by a Summer reception on June 27 in Brussels to present our participants’ key messaging and recommendations. \n\n\n\nIf you wish to attend our session or have any questions\, insights or suggestions\, please do not hesitate to reach José Peres at j.peres@europabio.org.  \n\n\n\nAgenda \n\n\n\nOpening remarks \n\n\n\n\nTineke Van hooland\, Deputy Secretary General at bio.be/essenscia\, Chair of the National Associations Council (NAC) at EuropaBio\n\n\n\n\nPanel I: Innovation for European Patients: the European pharmaceutical legislation \n\n\n\n\nMEP Dolors Montserrat (EPP)\n\n\n\nAna Polanco\, AseBio Chair of the Board\, Head of European Government and Public Affairs\, and Market Access and Pricing at Merck\n\n\n\nDr Jessica Martinsson\, Director General at SwedenBio\n\n\n\nMaria Pascual\, Chief Regulatory Officer at Minoryx Therapeutics\n\n\n\nModeration: Vlad Olteanu\, Healthcare Public Affairs Director at EuropaBio\n\n\n\n\nPanel II: Resilience\, sustainability and competitiveness for Europe’s food chain: new genomic techniques \n\n\n\n\nIlaria Ciabatti\, Team Leader Biotechnology Unit\, European Commission DG Santé\n\n\n\nIon Arocena Vélez\, Director General at AseBio – the Spanish Association of Biotechnology Companies\n\n\n\nElke Duwenig\, Senior Expert Global Regulatory / Public & Government Affairs Biotechnology\, Nutrition & Health at BASF\n\n\n\nOana Dima\, Executive Manager of the EU-SAGE network\, Science Policy Manager at VIB-Ghent University Center for Plant Systems Biology\n\n\n\nTomasz Zimny\,  Assistant Professor at the Institute of Law Studies\, Polish Academy of Sciences\, Warszawa\, Poland\n\n\n\nAna Judith Martín de la Fuente\, Head of Area/Secretary of the Interministerial Council of GMOs at the Spanish Ministry of Agriculture\, Food and Fisheries\n\n\n\nModeration: Anne-Gaelle Collot\, Industrial Biotechnology Director at EuropaBio\n\n\n\n\nClosing remarks \n\n\n\n\nClaire Skentelbery\, Director General at EuropaBio\n\n\n\n\n \n\n\n\n\nRegister here
URL:https://www.europabio.org/event/europabio-national-associations-council-summit-2023-spanish-presidency-a-global-europe-the-role-of-transformative-legislation/
ATTACH;FMTTYPE=image/jpeg:https://www.europabio.org/wp-content/uploads/2023/04/NAC-SUMMIT-BANNER-V2A.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20230616T083000
DTEND;TZID=Europe/Brussels:20230616T100000
DTSTAMP:20260526T205725
CREATED:20230524T085454Z
LAST-MODIFIED:20230524T142847Z
UID:6326-1686904200-1686909600@www.europabio.org
SUMMARY:GREEK BIOPHARMA INNOVATION: Your changing world with the new EU Pharma Legislation
DESCRIPTION:Chairperson: Claire Skentelbery\, Director General EuropaBio \n\n\n\nParticipants: \n\n\n\nKostas Papagiannis Country President & Managing Director Novartis Greece \n\n\n\nHardy Rideout Anacalypsis Therapeutics \n\n\n\nGeorge Drakakis CEO PurposefulEU pharma legislation is going to change your business. What you make\, where and how you sell it\, and whether your business model is even viable.The European Commission published new legislative proposals in April that will redefine the business model of biotechnology in Europe. In trying to bring medicines to more patients\, the legislation proposals reduce data protection\, limit exclusivity for orphan medicines and brings heavy pressure to launch in all 27 Member States within two years of EMA approval.Changing the rule book that has helped build Europe’s small company ecosystem over the last 20 years is going to have consequences for start-ups\, those seeking scale up investment\, clinical trials and companies going to market\, often for the first time.This session/panel\, chaired by EuropaBio\, presents the key impacts points for biotechnology innovation within Greece\, with contributions from small and large companies and policy makers – bring your voice to the discussion for the future of your own science. \n\n\n\n\nMore information
URL:https://www.europabio.org/event/greek-biopharma-innovation-your-changing-world-with-the-new-eu-pharma-legislation/
LOCATION:Megaron Athens International Conference Centre\, Athens\, Greece
CATEGORIES:External
ATTACH;FMTTYPE=image/jpeg:https://www.europabio.org/wp-content/uploads/2023/05/External-Events-Banners-600-×-200px-2.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20230615T080000
DTEND;TZID=Europe/Brussels:20230617T180000
DTSTAMP:20260526T205725
CREATED:20230516T094713Z
LAST-MODIFIED:20230516T104047Z
UID:6258-1686816000-1687024800@www.europabio.org
SUMMARY:3rd Hellenic Biocluster Forum
DESCRIPTION:The Hellenic BioCluster is organizing its 3rd Forum on the subject of “Supporting disruptive innovation to maximize the economic and social impact of the bio-industry sector”\, scheduled to be held between 15 – 17 June 2023 at Megaron Athens International Conference Centre\, Athens\, Greece. \n\n\n\nThe 3rd HBio Forum features a 3-day\, cutting-edge programme with inspiring speakers from across the globe\, all experts in disruptive innovation\, with the aim to connect the global biotech innovation community under the sunny Athens skies. During the Forum B2B meeting opportunities will be provided between attendees and sponsors/exhibitors. \n\n\n\nThe 3rd HBio Forum will also include targeted panels of industry experts\, mentors and life sciences professionals to discuss hot topics related to investment such as raising capital and achieving success\, followed by a Pitching Competition. \n\n\n\n\nMore Details
URL:https://www.europabio.org/event/3rd-hellenic-biocluster-forum/
LOCATION:Megaron Athens International Conference Centre\, Athens\, Greece
CATEGORIES:External
ATTACH;FMTTYPE=image/jpeg:https://www.europabio.org/wp-content/uploads/2023/05/External-Events-Banners-2.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20230605T173000
DTEND;TZID=Europe/Brussels:20230605T183000
DTSTAMP:20260526T205725
CREATED:20230523T115247Z
LAST-MODIFIED:20230524T142835Z
UID:6282-1685986200-1685989800@www.europabio.org
SUMMARY:EuropaBio: BIO 2023
DESCRIPTION:Round table –Biomanufacturing for health: advancing healthcare and global preparedness \n\n\n\n\n\nEuropaBio is pleased to host a round table discussion at the upcoming BIO International Convention in Boston and invites all delegates to join us to discuss on biomanufacturing for health: advancing healthcare and global prepareness.  \n\n\n\nBiomanufacturing within healthcare represents an advance in therapeutic capabilities\, as ground-breaking research translates into increased diseases that can be targeted\, either for the first time or with greater efficacy\, with increasingly complex interventions becoming possible. It also brings resilience and increased environmental sustainability to strained supply chains as the world strives to modernise production systems. \n\n\n\nThe transition has significant implications for global healthcare\, competitiveness\, sustainability and resilience\, with capacity building important in all regions. \n\n\n\nThis is not just reflected in advancing healthcare for citizens but also for the world’s ability to respond to healthcare crises.  Covid demonstrated that  biomanufacturing capacity globally was called into action from multiple applications and countries for the complex manufacturing process behind vaccines. \n\n\n\nThis biomanufacturing capacity does not exist within a vacuum\, ready to be called to action when needed. It requires drug developers large and small\, public and private\, specialised manufacturers\, plus skills base\, supply chain and logistics frameworks resulting from significant investment over many years. \n\n\n\nImportantly\, a sustainable biomanufacturing framework is financed and delivered primarily through industry\, meaning that is must be integral to company strategy. This is not a guarantee\, as the global healthcare industry reacts to legislative changes and government strategies\, with major investment decisions having long term implications for the capacity and skills base within countries and regions. \n\n\n\nWhat does the world need to get right to ensure that biomanufacturing capacity grows\, to serve patients with advancing therapies and be there for coordinated emergency responses? \n\n\n\nParticipants within the round table reflect global biomanufacturing stakeholders and will discuss: \n\n\n\n\nNational policies\, incentives and strategy\n\n\n\nRegulatory and standards and alignment\n\n\n\nInternational cooperation and development\n\n\n\n\nThe output from this roundtable will be a call to global action for biomanufacturing published through EuropaBio and BIO\, with all delegates invited to contribute through the round table and follow up. \n\n\n\nAgenda \n\n\n\n10:30Welcome and introductionEuropaBio and BIO10:40Setting the scene for global biomanufacturing and the planned outcome from the round tableClaire10:45(draft) Discussion points for participants: – What does your country need to achieve for resilience through national or accessible biomanufacturing capacity?– How are regulatory frameworks adapting to an increasingly biological pipeline of medicines?– What does international cooperation need to achieve to ensure that manufacturing is actually possible during pandemic responses?– Name a priority for you to reach biomanufacturing goals in the coming years.All participants: Lead interventions on specific topics11:30Closing remarksEuropaBio and BIO\n\n\n\n\n\n\n\n \n\n\n\n\nMore information here
URL:https://www.europabio.org/event/europabio-bio-2023/
LOCATION:Boston Convention & Exhibition Center\, Boston\, Massachusetts\, United States
CATEGORIES:EuropaBio
ATTACH;FMTTYPE=image/jpeg:https://www.europabio.org/wp-content/uploads/2023/05/Event-Banners-Website.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20230601T100000
DTEND;TZID=Europe/Brussels:20230601T190000
DTSTAMP:20260526T205725
CREATED:20230321T205822Z
LAST-MODIFIED:20230321T210149Z
UID:6071-1685613600-1685646000@www.europabio.org
SUMMARY:KNOWLEDGE FOR GROWTH 2023
DESCRIPTION:Knowledge for Growth is Europe’s finest life sciences conference.For the first time the event will take place in Antwerp.\n\n\n\nThe conference features an exciting programme providing vital insight into the global life sciences’ landscape\, one-to-one partnering\, a trade fair and more! \n\n\n\nLEARN. CONNECT. DISCOVER.\n\n\n\nThe cream of the Belgian life sciences community attends flanders.bio’s annual Knowledge for Growth business conference\, attracting decision makers from biotech\, pharma and medtech\, agricultural and chemical industry as well as investors\, universities\, top-notch research institutes\, policymakers and competence providers. \n\n\n\n\nMore information
URL:https://www.europabio.org/event/knowledge-for-growth-2023/
LOCATION:Flanders Meeting & Convention Center Antwerp\, Koningin Astridplein 26\, Antwerp\, 2018\, Belgium
CATEGORIES:External,Industrial Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2023/03/Event-Page-5.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20230526T100000
DTEND;TZID=Europe/Brussels:20230526T120000
DTSTAMP:20260526T205725
CREATED:20230523T140433Z
LAST-MODIFIED:20230523T141004Z
UID:6304-1685095200-1685102400@www.europabio.org
SUMMARY:ESAB-SusChem Webinar Sustainable Chemistry
DESCRIPTION:The European Society of Applied Biocatalysis (ESAB) and the European Technology Platform for Sustainable Chemistry (SUSCHEM) will held a Webinar on Sustainable Chemistry\, chaired by Pablo Domínguez de María (Sustainable Momentum SL\, ESAB Working Group Sustainable Chemistry\, SusChem Management Team) and Andrés R Alcántara (Complutense Univ of Madrid\, ESAB Working Group Sustainable Chemistry\, SusChem Board). \n\n\n\nPROGRAMME \n\n\n\n10:00 -10:30. MSc Irantzu Garmendia Aguirre\, Project Officer Safe and Sustainable by Design (SSbD)\, European Commission\, Directorate General Joint Research Centre\, Ispra\, Italy.Title: EC Recommendation for Safe and Sustainable by Design (SSbD) Chemicals Materials: scientific assessment framework policy context. \n\n\n\n10:30- 11:00. Prof. Dr. Dunming Zhu\, Tianjin Institute of Industrial Biotechnology\, Chinese Academy of Sciences\, Tianjin\, China.Title: Biocatalytic Synthesis of High Value Chemicals from Simple and/or Renewable Starting Materials. \n\n\n\n11:00-11:30. Dr. Fabrice Gallou\, Novartis Distinguished Scientist-Director Science & Technology Chemical Development\, Novartis\, Basel\, Switzerland.Title: Sustainability as a driver for innovation. \n\n\n\n11:30- 12:00. Prof. Dr. Dean Brady\, Molecular Sciences Institute\, School of Chemistry\, University of the Witwatersrand\, Johannesburg\, South Africa.Title: Biocatalysis in the synthesis of amines and amides. \n\n\n\n\nMore information here
URL:https://www.europabio.org/event/esab-suschem-webinar-sustainable-chemistry/
CATEGORIES:External
ATTACH;FMTTYPE=image/jpeg:https://www.europabio.org/wp-content/uploads/2023/05/External-Events-Banners-600-×-200px-1.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20230517T160000
DTEND;TZID=Europe/Brussels:20230517T163000
DTSTAMP:20260526T205725
CREATED:20230516T082719Z
LAST-MODIFIED:20230516T082807Z
UID:6226-1684339200-1684341000@www.europabio.org
SUMMARY:EU Healthcare and Pharmaceutical Policy in 2023: What You Need to Know
DESCRIPTION:From the ongoing revision of the EU pharmaceutical legislation package and addressing critical supply issues to the impact of the recent Medical Device Regulation transition period extension\, the challenges in EU healthcare and pharmaceutical policy are ever-evolving. Plus\, with the implementation of critical files\, such as the European Health Data Space (EHDS) and the Substances of Human Origin (SoHo) regulation\, it’s vital for organizations in this market to stay up-to-date with the latest policy and regulatory developments. \n\n\n\nTune in on May 17 at 4 pm CEST | 10 am EDT for a 30-minute recorded webinar that will delve into the latest updates in legislation and regulation that are shaping the future of healthcare\, pharmaceutical\, and medical device industries in Europe to help you navigate the next steps in this policy landscape. \n\n\n\nExperts will discuss: \n\n\n\n\nThe ongoing revision of EU pharmaceutical legislation\n\n\n\nTackling critical supply issues in pharmaceuticals and medical devices\n\n\n\nThe impact of the Medical Device Regulation transition period extension\n\n\n\nProposed and upcoming critical files you should be monitoring\n\n\n\nThe future of EU healthcare policy in 2023 and beyond\n\n\n\n\nFeatured speakers: \n\n\n\n\nAdrien Samson\, healthcare policy & public affairs senior manager\, EuropaBio\n\n\n\nJelle Verheij\, policy analyst – health and pharmaceuticals policy\, EU Issue Tracker\n\n\n\nModerator: Geraint Edwards\, managing director of FiscalNote Brussels\n\n\n\n\n\nMore Details
URL:https://www.europabio.org/event/eu-healthcare-and-pharmaceutical-policy-in-2023-what-you-need-to-know/
CATEGORIES:External,Healthcare Biotech
ATTACH;FMTTYPE=image/jpeg:https://www.europabio.org/wp-content/uploads/2023/05/General-Promo.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20230427T140000
DTEND;TZID=Europe/Brussels:20230427T151500
DTSTAMP:20260526T205725
CREATED:20230322T114230Z
LAST-MODIFIED:20230412T135959Z
UID:6092-1682604000-1682608500@www.europabio.org
SUMMARY:EuropaBio Biomanufacturing Policy Summit 2023: Where next for Europe?
DESCRIPTION:Summit outcomes and next steps \n\n\n\n\n\nOn 15th March\, EuropaBio hosted its first Biomanufacturing Policy Summit in Brussels\, with the aim of setting the vision for Europe’s global innovation\, competitiveness\, and sustainability on biomanufacturing\, while raising awareness among policy-makers. The Summit established a starting point\, a first step for a long journey that needs to be traveled by all stakeholders in Europe – SMEs\, large companies\, expert services\, and EU institutions – and which has already started in other parts of the world. \n\n\n\n80 attendees from industry\, national associations\, and stakeholders across the public and private spectrum presented\, debated\, and proposed.  In a fast-moving industrial transition\, calls for visionary policies\, enabling regulation\, and urgent action were some of the key takeaways from the summit. You can see the March 15th Summit agenda here. \n\n\n\nWould you like to find out more? \n\n\n\nJoin us on April 27 between 14:00 – 15:15 CET for a summit presentation and follow-up and add your voice to the discussion. This webinar will wrap up the main outcomes of the summit and lay the groundwork for future discussions. \n\n\n\nBiomanufacturing is key to the digital and green transitions and to securing a competitive and resilient future for Europe. Stay tuned for Europe’s future in biomanufacturing! \n\n\n\nAGENDA\n\n\n\n14:00: Welcome and introduction – Claire Skentelbery\, Director General\, EuropaBio \n\n\n\n14:10: Biomanufacturing Policy Summit report presentation – Virginia Claudio\, Sr Adviser & Programme Manager\, EuropaBio \n\n\n\nThe report presentation summarises the summit outcomes and builds policy recommendations for the development of the Biomanufacturing landscape in Europe. \n\n\n\n14:20: Report perspectives & reflections from healthcare and biotech industries\, and national associations – Sarah Moundir\, EU Public Affairs Senior Manager\, Novartis | Gwenael Servant\, Board Executive\, Abolis | Inga Matijosyte\, Vice President\, LithuaniaBIO \n\n\n\nA diverse group of stakeholders representing the wide spectrum of Biomanufacturing shares their views over the report outcomes\, as well as the priorities for their companies and organisations. \n\n\n\n14:50: Discussion and Q&A with the audience \n\n\n\nA discussion based on questions from the audience with a focus on the next steps for policy making on Biomanufacturing. \n\n\n\n15:10: Close – Closing remarks. \n\n\n\n\n\n\nRegister Here
URL:https://www.europabio.org/event/europabio-biomanufacturing-policy-summit-2023-where-next-for-europe/
CATEGORIES:Biomanufacturing Platform,EuropaBio
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2023/03/SM1-Quotes-Key-Messages-600-×-200px-2.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20230424T100000
DTEND;TZID=Europe/Brussels:20230425T190000
DTSTAMP:20260526T205725
CREATED:20230111T144716Z
LAST-MODIFIED:20230111T144717Z
UID:5648-1682330400-1682449200@www.europabio.org
SUMMARY:Swiss Biotech Day 2023
DESCRIPTION:The Swiss Biotech Day has become one of the leading biotechnology conferences in Europe and a fixed date in the community’s calendar. In 2022\, the conference demonstrated the impressive growth of the Swiss biotech industry and presented an exciting program with ideal networking opportunities for over 1\,100 participants across the globe. \n\n\n\nIn 2023\, the Swiss Biotech Day will again offer high-level experts from the life science industry the space to network\, discuss and discover trends in R&D\, manufacturing\, data management\, artificial intelligence and innovative financing over one and a half days. In addition\, international biotech delegations can take part in the “Global Village” to strengthen their ties with Switzerland as a biotech hub and promote cross-border investments\, public-private partnerships\, research and development collaborations and exchange of talent.  \n\n\n\nWe hope to see you in Basel on April 24-25\, 2023 in person again. \n\n\n\nWhat to expect: \n\n\n\n\nMeet 1.000+ senior experts from the life science industry\n\n\n\n70+ exhibitors and global village with international delegations from all over the world\n\n\n\nSwiss Biotech Success Stories Awards\n\n\n\nInnovative biotech start-ups and medium-sized biotech companies\n\n\n\nThematically focused panel discussions\n\n\n\nSwiss Biotech Report 2023\n\n\n\nPre-scheduled one-to-one partnering meetings\n\n\n\nGeneral Assembly of the Swiss Biotech Association\n\n\n\n\n\nMore information
URL:https://www.europabio.org/event/swiss-biotech-day-2023/
LOCATION:Congress Center Basel\, Messeplatz 21\, Basel\, 4058\, Switzerland
CATEGORIES:External,Industrial Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2023/01/Biomanufacturing-Policy-Summit-2023-2.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20230418T150000
DTEND;TZID=Europe/Brussels:20230418T160000
DTSTAMP:20260526T205725
CREATED:20230124T170639Z
LAST-MODIFIED:20230406T134218Z
UID:5708-1681830000-1681833600@www.europabio.org
SUMMARY:Development of Orphan Biologics: Challenges and Opportunities
DESCRIPTION:Webinar sponsored by Catalent \n\n\n\n\n\n\n\n\n\nThe development of therapies for rare diseases comes with distinct challenges\, including patient recruitment\, setting meaningful clinical endpoints\, manufacturing and supply and finding the regulatory and market pathway to ensure patients can access therapy. \n\n\n\nFor biologic products (growth factors\, monoclonal antibodies\, other complex proteins)\, development and production costs tend to be higher due to the complexity of the drug substance. To manage costs\, the clinical development and manufacturing and Chemistry\, Manufacturing and Controls (CMC) teams need to be aligned to ensure drug product is delivered on time to meet clinical trial needs. \n\n\n\nThese challenges sit within a wider regulatory and legislative framework for orphan medicinal products (OMPs) that defines whether companies can successfully develop a novel product to market and thus the decisions made for selecting therapeutics and target diseases early in development. \n\n\n\nDuring this webinar\, speakers cover aspects of clinical trial design for orphan biologics products\, key strategies for ensuring clinical trial supply throughout clinical development and the regulatory and legislative framework for delivery to patients.Key Learning Objectives \n\n\n\n\nConsiderations in identifying meaningful clinical endpoints for orphan diseases\n\n\n\nOrphan clinical trial design considerations and strategies to ensure sufficient patient recruitment\n\n\n\nManufacturing and clinical supply strategies to ensure supply of clinical trial materials while collecting data needed to support NDA submission\n\n\n\nRegulatory and legislative frameworks that guide decision making for innovation in rare diseases\n\n\n\n\nAgenda \n\n\n\n15:00: Welcome and introduction – Claire Skentelbery\, Director General EuropaBio \n\n\n\n15:05: Current Development of Orphan Drugs in Europe – Matthias Schoenermark\, Professor\, President and CEO\, SKC Beratungsgesellschaft mbH \n\n\n\nProf. Schönermark opens the session with an overview of the current status of orphan drug development in the EU. He discusses the main challenges for market entry of new orphan drugs into the EU market and highlights key recommendations to drug developers to address these challenges. \n\n\n\n15:20: Orphan Biologics and CGT Development – CMC and Clinical Trial Supply Considerations – Wai Lam Ling\, Ph.D.\, Vice President\, Science and Technology\,  Catalent \n\n\n\nDr. Ling discusses the difference in CMC challenges encountered during an orphan biologics vs CGT programme\, with a focus on product quality as the most significant hurdle to approval. She addresses manufacturing approaches to ensure regulatory compliance and factors behind a successful product\, particularly robust\, reproducible and cost-effective pathways. Finally\, supply chain liabilities are discussed\, with risks to production of biologics and their clinical supply. \n\n\n\n15:45: Successful Strategies and Business Model For Companies Bringing Their Orphan Drug To Market –Thomas Bols\, Head of Government Affairs and Patient Advocacy\, EMEA & APAC\, PTC Therapeutics \n\n\n\nThomas Bols addresses the spectrum of opportunities and barriers for innovation within orphan drug development\, particularly across different regulatory territories\, and the critical role of smaller companies in addressing unmet medical needs. He focuses on the legislative and regulatory pathways that exist in Europe for orphan drugs and the potential impact of the upcoming pharmaceutical and OMP legislation revisions for company innovation and patient benefits. \n\n\n\n16:00: Close \n\n\n\n\nRegister here
URL:https://www.europabio.org/event/development-of-orphan-biologics-challenges-and-opportunities/
LOCATION:Catalent
CATEGORIES:EuropaBio,External,Healthcare Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2023/01/Biomanufacturing-Policy-Summit-2023-5.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20230418T100000
DTEND;TZID=Europe/Brussels:20230419T190000
DTSTAMP:20260526T205725
CREATED:20230110T150742Z
LAST-MODIFIED:20230110T151000Z
UID:5629-1681812000-1681930800@www.europabio.org
SUMMARY:CEBioForum 2023
DESCRIPTION:CEBioForum is a brand that has been creating a business environment related to biotechnology for over 20 years\, organizing the most important event of this type in the industry\, dedicated to the development of biotechnology in Poland and Europe \n\n\n\nCEBioForum 2023 will take place on April 18-19 in Warsaw \n\n\n\nBecause we strongly believe that networking is the basis for building lasting business relationships\, CEBioForum 2023 is held only face-to-face\, giving you a chance to make new connections with business partners\, scientists and decision makers from the government\, who contribute to biotech development in Poland and other CEE countries. \n\n\n\nCEBioForum 2023 is more then discussion panels\, networking and the opportunity to present your company. During the conference banquete\, we will honor outstanding people and companies with CEBioForum Awards 2023. \n\n\n\nSo save the date 18-19th of April and be with us in Warsaw at CEBioForum 2023. \n\n\n\n\nMore information
URL:https://www.europabio.org/event/cebioforum-2023/
CATEGORIES:External
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2023/01/Biomanufacturing-Policy-Summit-2023-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20230328T100000
DTEND;TZID=Europe/Brussels:20230329T190000
DTSTAMP:20260526T205725
CREATED:20230320T155641Z
LAST-MODIFIED:20230320T155643Z
UID:6060-1679997600-1680116400@www.europabio.org
SUMMARY:German Biotech Days 2023
DESCRIPTION:Germany’s largest biotech event\, the German Biotechnology Days 2023 (Deutsche Biotechnologietage\, DBT)\, will take place on March 28th and 29th in Wiesbaden. The event is the national forum for the German biotechnology industry. The DBT brings together entrepreneurs with scientists and partners from politics\, funding institutions and administration. The two-day program highlights the diverse fields of application and the potential of biotechnology\, from health research to the bioeconomy. \n\n\n\nThe German Biotechnology Days are jointly organised by BIO Deutschland and the Council of German BioRegions. The host region for 2023 is Technologieland Hessen from Wiesbaden\, and we were able to win Infectognostics Forschungscampus Jena as another partner region. \n\n\n\n\nMore information
URL:https://www.europabio.org/event/german-biotech-days-2023/
CATEGORIES:External,Industrial Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2023/03/Event-Page-6.png
END:VEVENT
END:VCALENDAR